Please login to the form below

Not currently logged in

EMD Serono president James Hoyes joins consultants RxC

Takes up a role as executive partner at the US management consulting firm

RxC International EMD Serono James HoyesJames Hoyes has joined RxC International as an executive partner, having worked for the New Jersey management consulting firm as a senior advisor since 2014.

He was previously president of EMD Serono - as the US biopharma operations of Germany's Merck are known - having initially joined the company in 2004 as VP of neurology marketing.

Hoyes subsequently held roles as executive vice president, managing EMD Serono's neurology sales, marketing, comms, call centre and medical affairs operations, and as chief commercial officer.

Prior to joining EMD Serono, Hoyes held leadership positions with the likes of Serono, Elan and Sanofi.

In his new consultancy role he will provide advisory services to RxC's clients, work on corporate development initiatives in life sciences and implement key strategic initiatives to scale up the firm's global operations.

RxC International managing partner Subbarao Jayanthi said: “Jim's addition represents another milestone in the expansion of our business. He has an outstanding track record as a leader in the life sciences sector, and his deep strategic and executive leadership expertise will be invaluable to our clients.”

12th August 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...